Novartis acquires Chinook Therapeutics for $3.5B to advance kidney disease treatment.
TL;DR Summary
Novartis is set to acquire Chinook Therapeutics, a biotech company focused on kidney disease, for $3.2 billion in cash. The acquisition includes two late-stage drugs for a rare chronic kidney disease. Novartis already has a top drug for IgA nephropathy, but Chinook's atrasentan and zigakibart could provide additional options for patients.
- Novartis to buy out kidney specialist Chinook Therapeutics in $3.5B deal Endpoints News
- Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease Reuters
- Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG Yahoo Finance
- Novartis inks $3.2B Chinook buyout to lift kidney disease plans FierceBiotech
- Why Shares of Chinook Therapeutics Skyrocketed On Monday The Motley Fool
Reading Insights
Total Reads
0
Unique Readers
29
Time Saved
0 min
vs 1 min read
Condensed
51%
104 → 51 words
Want the full story? Read the original article
Read on Endpoints News